| 401 |
27618759 | Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment. | 2016 Dec |
2 |
| 402 |
27641462 | [Osimertinib (Tagrisso®): Activity, indication and modality of use in non-small cell lung cancer]. | 2016 Oct |
2 |
| 403 |
27649127 | Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. | 2016 Sep 15 |
4 |
| 404 |
27660466 | Osimertinib making a breakthrough in lung cancer targeted therapy. | 2016 |
6 |
| 405 |
27694386 | Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. | 2016 Dec |
2 |
| 406 |
27751845 | Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat. | 2016 Dec |
1 |
| 407 |
27751847 | Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. | 2016 Dec |
8 |
| 408 |
27770386 | Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. | 2016 Dec |
1 |
| 409 |
27784815 | Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience. | 2016 Dec |
2 |
| 410 |
27835594 | Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line. | 2016 Dec 6 |
6 |
| 411 |
27861144 | Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma. | 2016 Dec 27 |
4 |
| 412 |
27910964 | Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations. | 2016 Oct |
2 |
| 413 |
28149764 | Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. | 2016 Dec |
3 |
| 414 |
28149837 | Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. | 2016 |
3 |
| 415 |
30643560 | AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC. | 2016 Dec |
2 |
| 416 |
26515464 | In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. | 2015 Nov 17 |
3 |